Telma CT 80/6.25 mg Tablet

• Manage high blood pressure

Telma CT 80/6.25mg tablet cause side effects just like any other medication have. Patients experience acute as well mild symptoms while using the medication. Consult the healthcare expert if any of these conditions persist or worsen:

• Dizziness

• Headache

• Fatigue

• Increased urination

• Muscle cramps or weakness

• Low blood pressure symptoms

• Allergic reactions (e.g., swelling of the face, lips, tongue, or throat, difficulty breathing, rash)

• Severe dizziness

• Light headedness

• Fainting

• High potassium levels (muscle weakness, irregular heartbeat)

• Liver problems

• Medication dosage and duration are monitored by healthcare professional to avoid complications during the treatment. Telma CT 80/6.25mg tablet should be taken with or without food at the fixed time everyday to improve the treatment outcomes.
• Never self administer the dosage or stop the medication without consulting to a doctor, as improper use may lead to serious health complications.​​
  

Telma CT 80/6.25mg tablet helps to lower blood pressure, where Telmisartan works by blocking angiotensin, a hormone responsible for regulating blood pressure and maintain fluid balance in the body.

Whereas, Chlorthalidone works by removing extra water and certain electrolytes from the body through urine, helping to reduce blood volume and ease the workload on the heart, Overall, the medicine effects to control blood pressure.​

• Destro, M., Cagnoni, F., Dognini, G. P., Galimberti, V., Taietti, C., Cavalleri, C., & Galli, E. (2011). Telmisartan: just an antihypertensive agent? A literature review. Expert opinion on pharmacotherapy, 12(17), 2719-2735. https://pubmed.ncbi.nlm.nih.gov/22077832/

• Deppe, S., Böger, R. H., Weiss, J., & Benndorf, R. A. (2010). Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert opinion on drug metabolism & toxicology, 6(7), 863-871. https://pubmed.ncbi.nlm.nih.gov/20509777/

• Ontarget Investigators. (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine, 358(15), 1547-1559. https://pubmed.ncbi.nlm.nih.gov/18378520/

• Wienen, W., Entzeroth, M., van Meel, J. C., Stangier, J., Busch, U., Ebner, T., ... & Hauel, N. H. (2000). A review on telmisartan: a novel, long‐acting angiotensin II‐receptor antagonist. Cardiovascular drug reviews, 18(2), 127-154. https://pmc.ncbi.nlm.nih.gov/articles/PMC1993985/

• Mann, J. F., Schmieder, R. E., Dyal, L., McQueen, M. J., Schumacher, H., Pogue, J., ... & TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. (2009). Effect of telmisartan on renal outcomes: a randomized trial. Annals of internal medicine, 151(1), 1-10.